What You Should Know:
- ARC Innovation, the world’s premier ecosystem powering global health transformation, announced today the launch of ARC Accelerator, a new accelerator within the Sheba Medical Center campus.
- Aligned with the launch of the new accelerator, Ilex Medical Ltd. (TLV: ILX), part of the Ilex Group, will invest $10M into ARC Accelerator. This landmark initiative aims to empower early-stage companies through financial backing, expert guidance, and an unparalleled support network.
Revolutionizing Startup Support and Funding in Israeli Innovation
The ARC Accelerator program, which caters to both Israeli and international innovation companies, leads the way in providing a dynamic combination of professional guidance, engaging content, and interactive sessions aimed at delivering short and long-term value to participants. Focusing on three pivotal tracks—Senior Health, Women’s Health, and Behavioral/Mental Health—the program spans 10 to 14 weeks and supports 8-10 startups in each cohort. Its format, blending face-to-face sessions with online interactions, incorporates mentorship based on esteemed models like MIT’s Venture Mentoring Service. As an integral part of Sheba Medical Center, the program grants ARC Accelerator participants access to Sheba’s clinical expertise, global partnerships, educational insights, and investor relations. Entrepreneurs gain direct access to a robust support network, including the Sheba School of Entrepreneurship and Innovation, and exposure to the Sheba ARC Angels’ Club. This diverse ecosystem ensures that startups leverage funding opportunities tailored to their specific stages of development.
Distinctively, ARC Accelerator introduces a novel financial model to the Israeli accelerator ecosystem by providing significant funding to participating startups. Companies also enjoy perks such as free office space for a year, membership in a growing alumni network, and collaboration prospects beyond Israel through ARC’s extensive network of premier health systems and strategic partners. The funding structure offers $125,000 on a post-money SAFE for a 7.5% equity stake, along with an additional $125,000 on an uncapped SAFE featuring a Most Favored Nation (MFN) provision, with Uniform funding terms applying to all startups.
“The new accelerator will be a central part of implementing ARC’s vision of leading transformation processes in healthcare systems worldwide,” said Prof. Eyal Zimlichman, CEO of ARC Innovation and Chief Innovation and Chief Transformation Officer of Sheba Medical Center. “We aim to support the leading entrepreneurs in Israel and believe in our ability to guide entrepreneurs at various stages to realizing their potential. We believe this can significantly influence economic growth in Israel and within the global healthcare market.”
